HK1051142A1 - Formulation of substituted benzimidazoles - Google Patents

Formulation of substituted benzimidazoles

Info

Publication number
HK1051142A1
HK1051142A1 HK03103347A HK03103347A HK1051142A1 HK 1051142 A1 HK1051142 A1 HK 1051142A1 HK 03103347 A HK03103347 A HK 03103347A HK 03103347 A HK03103347 A HK 03103347A HK 1051142 A1 HK1051142 A1 HK 1051142A1
Authority
HK
Hong Kong
Prior art keywords
formulation
substituted benzimidazoles
benzimidazoles
substituted
Prior art date
Application number
HK03103347A
Other languages
English (en)
Inventor
Mikael Brulls
Original Assignee
Astrazeneca Ab
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Astrazeneca Ab filed Critical Astrazeneca Ab
Publication of HK1051142A1 publication Critical patent/HK1051142A1/xx

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/10—Alcohols; Phenols; Salts thereof, e.g. glycerol; Polyethylene glycols [PEG]; Poloxamers; PEG/POE alkyl ethers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A61K47/32—Macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. carbomers, poly(meth)acrylates, or polyvinyl pyrrolidone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Inorganic Chemistry (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Dermatology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Plural Heterocyclic Compounds (AREA)
HK03103347A 1999-10-22 2003-05-13 Formulation of substituted benzimidazoles HK1051142A1 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
SE9903831A SE9903831D0 (sv) 1999-10-22 1999-10-22 Formulation of substituted benzimidazoles
PCT/SE2000/001992 WO2001028558A1 (en) 1999-10-22 2000-10-13 Formulation of substituted benzimidazoles

Publications (1)

Publication Number Publication Date
HK1051142A1 true HK1051142A1 (en) 2003-07-25

Family

ID=20417464

Family Applications (1)

Application Number Title Priority Date Filing Date
HK03103347A HK1051142A1 (en) 1999-10-22 2003-05-13 Formulation of substituted benzimidazoles

Country Status (36)

Country Link
US (1) US6730685B1 (es)
EP (1) EP1274427B1 (es)
JP (1) JP2003512327A (es)
KR (1) KR100785603B1 (es)
CN (1) CN1213751C (es)
AR (1) AR029005A1 (es)
AT (1) ATE304851T1 (es)
AU (1) AU782866B2 (es)
BG (1) BG65580B1 (es)
BR (1) BR0014895A (es)
CA (1) CA2425199C (es)
CO (1) CO5261533A1 (es)
CY (1) CY1106055T1 (es)
CZ (1) CZ20021375A3 (es)
DE (1) DE60022789T2 (es)
DK (1) DK1274427T3 (es)
EE (1) EE05175B1 (es)
ES (1) ES2246903T3 (es)
HK (1) HK1051142A1 (es)
HU (1) HUP0203121A3 (es)
IL (2) IL149107A0 (es)
IS (1) IS2196B (es)
MX (1) MXPA02003900A (es)
MY (1) MY131971A (es)
NO (1) NO329545B1 (es)
NZ (1) NZ518155A (es)
PL (1) PL199868B1 (es)
RU (1) RU2286782C2 (es)
SE (1) SE9903831D0 (es)
SI (1) SI1274427T1 (es)
SK (1) SK286266B6 (es)
TR (1) TR200201103T2 (es)
TW (1) TWI236372B (es)
UA (1) UA74347C2 (es)
WO (1) WO2001028558A1 (es)
ZA (1) ZA200202905B (es)

Families Citing this family (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2417311C (en) * 2000-08-04 2012-07-10 Takeda Chemical Industries, Ltd. Crystalline alkali metal salts of lansoprazole and their production and use
US7396841B2 (en) * 2000-08-18 2008-07-08 Takeda Pharmaceutical Company Limited Injections
MY137726A (en) * 2000-11-22 2009-03-31 Nycomed Gmbh Freeze-dried pantoprazole preparation and pantoprazole injection
GB2376231A (en) * 2001-06-06 2002-12-11 Cipla Ltd Benzimidazole-cyclodextrin inclusion complex
FR2845916B1 (fr) * 2002-10-21 2006-07-07 Negma Gild Composition pharmaceutique associant le tenatoprazole et un antagoniste des recepteurs h2 a l'histamine
FR2845917B1 (fr) * 2002-10-21 2006-07-07 Negma Gild Composition pharmaceutique associant le tenatoprazole et un anti-inflammatoire
FR2845915B1 (fr) * 2002-10-21 2006-06-23 Negma Gild Utilisation du tenatoprazole pour le traitement du reflux gastro-oesophagien
FR2848555B1 (fr) * 2002-12-16 2006-07-28 Negma Gild Enantiomere(-)du tenatoprazole et son application en therapeutique
US7507746B2 (en) * 2003-02-24 2009-03-24 Mitsubishi Pharma Corporation Enantiomer of tenatoprazole and the use thereof in therapy
TWI372066B (en) * 2003-10-01 2012-09-11 Wyeth Corp Pantoprazole multiparticulate formulations
US20060089376A1 (en) * 2004-10-27 2006-04-27 Joshi Ramesh A Tenatoprazole salts and process of preparation thereof
BRPI0711048A2 (pt) * 2006-05-09 2011-08-23 Astrazeneca Ab formulações parenteral esterilizada e sólida estáveis, solução para administração parenteral, processos para a preparação de uma formulação e para a fabricação de um produto, método para prevenir ou tratar doenças gastrintestinais, uso de uma formulação sólida estável
CN100411613C (zh) * 2006-12-08 2008-08-20 中国药科大学 一种奥美拉唑速释固体制剂及其制备方法
US10415073B2 (en) 2014-11-13 2019-09-17 3M Innovative Properties Company Kit comprising ATP-diphosphohydrolase for detecting bacterial ATP in a sample
EP3288556A4 (en) 2015-04-29 2018-09-19 Dexcel Pharma Technologies Ltd. Orally disintegrating compositions
US10076494B2 (en) 2016-06-16 2018-09-18 Dexcel Pharma Technologies Ltd. Stable orally disintegrating pharmaceutical compositions

Family Cites Families (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
SE7804231L (sv) 1978-04-14 1979-10-15 Haessle Ab Magsyrasekretionsmedel
SE8301182D0 (sv) * 1983-03-04 1983-03-04 Haessle Ab Novel compounds
IL75400A (en) 1984-06-16 1988-10-31 Byk Gulden Lomberg Chem Fab Dialkoxypyridine methyl(sulfinyl or sulfonyl)benzimidazoles,processes for the preparation thereof and pharmaceutical compositions containing the same
JPS6150978A (ja) 1984-08-16 1986-03-13 Takeda Chem Ind Ltd ピリジン誘導体およびその製造法
AU4640985A (en) 1984-08-31 1986-03-06 Nippon Chemiphar Co. Ltd. Benzimidazole derivatives
DK399389A (da) * 1988-08-18 1990-02-19 Takeda Chemical Industries Ltd Injicerbare oploesninger
JP2536173B2 (ja) * 1988-08-18 1996-09-18 武田薬品工業株式会社 注射剤
KR930000861B1 (ko) * 1990-02-27 1993-02-08 한미약품공업 주식회사 오메프라졸 직장투여 조성물
WO1994002141A1 (en) 1992-07-28 1994-02-03 Astra Aktiebolag Injection and injection kit containing omeprazole and its analogs
SE9301830D0 (sv) 1993-05-28 1993-05-28 Ab Astra New compounds
TW359614B (en) 1993-08-31 1999-06-01 Takeda Chemical Industries Ltd Composition containing benzimidazole compounds for rectal administration
US5726181A (en) 1995-06-05 1998-03-10 Bionumerik Pharmaceuticals, Inc. Formulations and compositions of poorly water soluble camptothecin derivatives
US5840737A (en) 1996-01-04 1998-11-24 The Curators Of The University Of Missouri Omeprazole solution and method for using same
US5877205A (en) 1996-06-28 1999-03-02 Board Of Regents, The University Of Texas System Parenteral paclitaxel in a stable non-toxic formulation
SE510643C2 (sv) 1997-06-27 1999-06-14 Astra Ab Termodynamiskt stabil omeprazol natrium form B
CA2318128C (en) * 1998-01-20 2008-10-14 Applied Analytical Industries, Inc. Oral liquid compositions

Also Published As

Publication number Publication date
NO329545B1 (no) 2010-11-08
KR20020059637A (ko) 2002-07-13
SK286266B6 (sk) 2008-06-06
BR0014895A (pt) 2002-06-18
TR200201103T2 (tr) 2002-08-21
UA74347C2 (uk) 2005-12-15
AU1182301A (en) 2001-04-30
PL199868B1 (pl) 2008-11-28
CN1213751C (zh) 2005-08-10
IL149107A (en) 2008-04-13
DE60022789D1 (de) 2006-02-02
DE60022789T2 (de) 2006-06-22
CZ20021375A3 (cs) 2002-09-11
CY1106055T1 (el) 2011-04-06
CA2425199A1 (en) 2001-04-26
TWI236372B (en) 2005-07-21
AR029005A1 (es) 2003-06-04
DK1274427T3 (da) 2005-12-27
SK5392002A3 (en) 2002-10-08
BG106602A (en) 2002-12-29
AU782866B2 (en) 2005-09-01
BG65580B1 (bg) 2009-01-30
EP1274427A1 (en) 2003-01-15
CA2425199C (en) 2010-12-07
SE9903831D0 (sv) 1999-10-22
EE05175B1 (et) 2009-06-15
NO20021860L (no) 2002-05-21
NZ518155A (en) 2004-07-30
WO2001028558A1 (en) 2001-04-26
CN1382048A (zh) 2002-11-27
ATE304851T1 (de) 2005-10-15
RU2286782C2 (ru) 2006-11-10
KR100785603B1 (ko) 2007-12-14
CO5261533A1 (es) 2003-03-31
EP1274427B1 (en) 2005-09-21
US6730685B1 (en) 2004-05-04
IS2196B (is) 2007-01-15
ZA200202905B (en) 2003-07-14
HUP0203121A3 (en) 2004-01-28
HUP0203121A2 (hu) 2003-01-28
EE200200204A (et) 2003-04-15
JP2003512327A (ja) 2003-04-02
IL149107A0 (en) 2002-11-10
IS6347A (is) 2002-04-17
MXPA02003900A (es) 2002-09-30
PL354926A1 (en) 2004-03-22
ES2246903T3 (es) 2006-03-01
SI1274427T1 (sl) 2006-02-28
NO20021860D0 (no) 2002-04-19
MY131971A (en) 2007-09-28

Similar Documents

Publication Publication Date Title
HUP0202028A2 (en) Substituted benzimidazole
HK1044329A1 (en) Concrete formulation
PL337773A1 (en) Derivatives of benzimidazoles
EP1387680A4 (en) AGENTS TH RAPEUTICES D RIV S BENZIMIDAZOLE BASE
HUP0201489A3 (en) New formulation
EG24226A (en) Formulation
AU2403802A (en) Benzimidazole derivatives
IL155937A0 (en) Imidazole and benzimidazole derivatives and pharmaceutical compositions containing the same
HK1051142A1 (en) Formulation of substituted benzimidazoles
EP1145707A4 (en) COMPOSITIONS FOR OUTSIDE USE
HUP0200735A3 (en) Anthelmintic compositions
GB9905898D0 (en) Controlled-dose formulation
EG22530A (en) Preparation of substituted piperidin-4-ones
IL148777A0 (en) New formulation of mirtazapine
GB9902304D0 (en) Formulation
PL352409A1 (en) Derivatives of 1-trifluorometyl-4-hydroxy-7-piperidinyl-aminomethylochromane
EP1218407A4 (en) USES OF KAPPA-CONOTOXIN PVIIA
HK1048633A1 (zh) 製備3-替代-4芳基喹啉-2-一衍生物
GB9927614D0 (en) Sterliant formulation
PL350963A1 (en) Use of arylalkanoylpyridazines
HUP0203900A3 (en) Use of substituted 4-amino-1-phenylbutan-2-ol compounds as medicaments
IL147232A0 (en) Stable benzimidazole formulation
GB9902236D0 (en) Formulation
GB9917952D0 (en) Formulation
GB9923538D0 (en) Formulation

Legal Events

Date Code Title Description
PC Patent ceased (i.e. patent has lapsed due to the failure to pay the renewal fee)

Effective date: 20121013